In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

Company Newsletters

Imugene is committed to keeping our shareholders up to date with all of the developments.  Click on the newsletter to download a full copy.  To receive the next newsletter immediately via email, sign up now.

Subscribe to our mailing list

* indicates required
Are you a shareholder? *
Email Format
 
 
 

© Imugene 2017. All rights reserved. ABN 99 009 179 551